Get started
Author

S. Blanch

Gestational breast cancer: distinctive molecular and clinico-epidemiological features
2024 · J. R. de la Haba-Rodríguez, P. Mínguez, et al. · Journal of Mammary Gland Biology and Neoplasia · 9
PDF
330TiP Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
2021 · M. Vaz Batista, J.M. Pérez-Garcia, et al. · Annals of Oncology · 4
41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)
2020 · L. Manso, P. Villagrasa, et al. · Annals of Oncology · 2
VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial
2017 · B. Adamo, J.A. Perez Fidalgo, et al. · Annals of Oncology · 2
PDF
260P LUZERN: Phase II trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer
2024 · S. Blanch, J. Balmaña, et al. · ESMO Open · 1
258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED
2023 · J.M. Pérez-García, M. Gion Cortes, et al. · ESMO Open · 1
PDF
339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer
2021 · L. Manso, S. Pernas, et al. · Annals of Oncology · 1
PDF
129TiP Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR)[+]/HER2[–] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
2021 · A. Llombart Cussac, J.M. Pérez-Garcia, et al. · Annals of Oncology · 1
PDF
Long-term follow up of patients with dystrophin deficiency and isolated hyperCKemia
2015 · P. Marti, N. Muelas, et al. · Neuromuscular Disorders · 1
35 High pathologic complete remission rate with liposome-encapsulated doxorubicin + paclitaxel + trastuzumab as primary treatment in HER-2 positive operable breast cancer: clinical experience
2010 · J. Gavila, A. Guerrero-Zotano, et al. · European Journal of Cancer Supplements · 1
346P Sacituzumab govitecan (SG) in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) within routine clinical practice in Spain (TROPSPAIN): Interim analysis of a retrospective, observational, multicentre study
2025 · M. Munoz, M. Fernandez Abad, et al. · ESMO Open
220P Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (aBC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial
2024 · A. Llombart-Cussarc, J.M. Pérez García, et al. · ESMO Open
PDF
205TiP ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
2022 · A. Cortés Salgado, J.M. Perez Garcia, et al. · Annals of Oncology
182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer (ABC). The LUZERN Strategy
2020 · S. Blanch, J.M. Pérez-García, et al. · Annals of Oncology
Abstract P3-14-09: Hyperglycemia secondary to everolimus is associated with a prognosis improvement in hormone-sensitive metastatic breast cancer. A retrospective analysis
2019 · S Sandiego, MA Algarra, et al. · Cancer Research
Abstract P5-11-04: Anti-proliferative effect of oral metronomic vinorelbine (mVNB) in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): A randomized, three-arm, window-of-opportunity study
2019 · A Prat, B Adamo, et al. · Cancer Research
Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study
2018 · A. Prat, B. Adamo, et al. · Annals of Oncology
Abstract P2-09-27: Integrated analysis of PTEN protein expression and PI3KCA mutations as predictors for pathological complete response in HER2-positive breast cancer
2018 · J Gavila, F Gozalbo, et al. · Cancer Research
Prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancers (TNBC) treated with neoadjuvant chemotherapy (NAC)
2016 · C. Herrero-Vicent, A. Guerrero, et al. · Annals of Oncology
Genomic Characterization of Early Stages of Ovarian Cancer with Emphasis in Low-Grade Endometroid and Low-Grade Serous Histologies. a Study By Spanish Group for Ovarian Cancer Research (Geico)
2014 · I. Romero, J.A. Lopez Guerrero, et al. · Annals of Oncology
25 Influence of pathologic tumour characteristics on ipsilateral breast tumour recurrences after breast conservation and neoadjuvant chemotherapy
2010 · A. Guerrero Zotano, J. Gavilá, et al. · European Journal of Cancer Supplements
Works count: 21
Citation count: 23
H-index: 2
I10-index:
Year
Topic
Type